PepGen Inc. is a biotechnology firm focused on the development of innovative therapies for treating genetic diseases. Utilizing its proprietary peptide-based technology platform, the company aims to advance the treatment options for patients suffering from a range of neuromuscular and central nervous system disorders. PepGen is dedicated to harnessing the power of targeted delivery of genetic medicines to improve patient outcomes and support the growing demand for effective gene therapies in the healthcare landscape. Through rigorous research and development, PepGen seeks to bring transformative solutions to underserved medical needs. Read More
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about September 26, 2025, subject to customary closing conditions. In addition, PepGen has granted the underwriters a 30-day option to purchase up to 4,687,500 additional shares of common stock at the public offering price, less the underwriting discount.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. In addition, PepGen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results demonstrated a mean splicing correction of 53.7% following a single 15 mg/kg dose of PGN-EDODM1, substantially higher than any previously reported splicing correction in DM1 patients.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options
PepGen reported a Q2 2025 net loss of $23.1M, beating EPS estimates. Clinical progress in DM1 trials and stable cash position highlight the update. Stock shows mixed performance amid legal scrutiny.
NEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025.
NEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.
